ribociclib will raise the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
enzalutamide will lower the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep track of Intently. Coadministration of fentanyl with CYP3A4 inducers could lead on to some reduce in fentanyl plasma concentrations, insufficient efficacy or, possibly, growth of a withdrawal syndrome inside of a affected individual who's got developed Bodily dependence to fentanyl.
dabrafenib will lessen the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep an eye on Closely. Coadministration of fentanyl with CYP3A4 inducers could lead on to your reduce in fentanyl plasma concentrations, not enough efficacy or, potentially, advancement of a withdrawal syndrome in a individual who may have designed Actual physical dependence to fentanyl.
If coadministration of CYP3A4 inhibitors with fentanyl is critical, watch patients for respiratory depression and sedation at Regular intervals and consider fentanyl dose changes right up until stable drug effects are achieved.
larotrectinib will increase the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
Repotrectinib is often a CYP3A4 inducer. Stay clear of coadministration with CYP3A substrates where Fentanyl negligible concentration changes can cause reduced efficacy, Except if otherwise encouraged their prescribing information.
If coadministration of CYP3A4 inhibitors with fentanyl is critical, keep track of patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose changes until eventually stable drug effects are attained.
Observe Carefully (two)fentanyl will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Observe Intently (one)nirmatrelvir will increase the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
dexamethasone will decrease the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Closely. Coadministration of fentanyl with CYP3A4 inducers could lead on to some lower in fentanyl plasma concentrations, lack of efficacy or, possibly, progress of a withdrawal syndrome in a patient who's got developed Bodily dependence to fentanyl.
mobocertinib will lessen the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate Drug. If use is unavoidable, increase CYP3A4 substrate dosage in accordance with its prescribing information.
trofinetide will enhance the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Use in patients with acute or extreme bronchial bronchial asthma within an unmonitored placing or in absence of resuscitative equipment is contraindicated; patients with important chronic obstructive pulmonary sickness or cor pulmonale, and with substantially reduced respiratory reserve, hypoxia, hypercapnia, or pre-current respiratory depression are at amplified risk of decreased respiratory generate which include apnea, even at advisable dosages
diazepam intranasal and fentanyl both of those maximize sedation. Stay clear of or Use Alternate Drug. Restrict use to patients for whom alternate treatment options are insufficient